AKPRO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AKPRO (AKPRO).
Inhibits P2Y12 platelet receptor, blocking ADP-mediated platelet aggregation.
| Metabolism | Prodrug; metabolized to active metabolite primarily via CYP2C19, with contributions from CYP3A4, CYP2C9, CYP2B6 |
| Excretion | Renal excretion of unchanged drug accounts for approximately 1-2% of an administered dose; the remainder is metabolized in ocular tissues and eliminated via nasolacrimal drainage and gastrointestinal tract, with minimal systemic absorption. Biliary/fecal excretion is negligible. |
| Half-life | Terminal elimination half-life: approximately 2-3 hours in aqueous humor; systemic half-life is negligible due to low plasma concentrations. |
| Protein binding | Approximately 60-70% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Due to minimal systemic absorption, volume of distribution data is not clinically relevant; for the fraction absorbed, estimated Vd is approximately 0.2-0.4 L/kg. |
| Bioavailability | Ocular instillation: systemic bioavailability is low (<1%) due to extensive first-pass metabolism in the nasal mucosa and gastrointestinal tract after nasolacrimal drainage. |
| Onset of Action | Ocular instillation: reduction in intraocular pressure observed within 1-2 hours; peak effect at 2-4 hours. |
| Duration of Action | Ocular instillation: intraocular pressure reduction maintained for up to 12-24 hours with once-daily dosing. |
1 drop of 0.45% solution in each eye once daily in the evening or as directed by physician.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No specific renal dose adjustments recommended; use with caution in severe renal impairment (CrCl <30 mL/min) due to potential systemic accumulation. |
| Liver impairment | No specific hepatic dose adjustments recommended; use with caution in severe hepatic impairment (Child-Pugh Class C) due to lack of data. |
| Pediatric use | Safety and effectiveness in pediatric patients have not been established; use is not recommended. |
| Geriatric use | No specific dose adjustments in elderly; use same as adult dosing, with monitoring for ocular adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for AKPRO (AKPRO).
| Breastfeeding | Excreted in breast milk in low amounts (M/P ratio not reported). Use with caution due to potential adverse effects on infant (e.g., gastrointestinal, renal). Short-term use is generally considered acceptable. |
| Teratogenic Risk | Category C. First trimester: Based on animal studies, may cause fetal harm. No adequate human studies. Second and third trimesters: Risk of premature closure of ductus arteriosus and oligohydramnios with NSAID use after 20 weeks gestation. |
| Fetal Monitoring |
■ FDA Black Box Warning
Efficacy depends on active metabolite formation; reduced efficacy in CYP2C19 poor metabolizers. Avoid use in patients with active pathological bleeding or history of transient ischemic attack/stroke.
| Serious Effects |
Active pathological bleeding (e.g., peptic ulcer, intracranial hemorrhage); history of transient ischemic attack or stroke; severe hepatic impairment; hypersensitivity to AKPRO or any component.
| Precautions | Bleeding risk, especially in patients undergoing surgery; thrombotic thrombocytopenic purpura (TTP) reported; premature discontinuation increases cardiovascular event risk; CYP2C19 poor metabolizers may have reduced efficacy. |
| Food/Dietary | No known food interactions. |
Loading safety data…
| Monitor fetal ductus arteriosus and amniotic fluid volume with ultrasound if used beyond 20 weeks gestation. Assess maternal renal function and bleeding time. |
| Fertility Effects | May impair female fertility via inhibition of prostaglandin synthesis affecting ovulation. Reversible upon discontinuation. |
| Clinical Pearls | AKPRO is a combination ophthalmic solution containing proparacaine 0.5% and fluorescein sodium 0.25%. Use only for diagnostic procedures; never dispense for patient self-administration due to risk of corneal toxicity with repeated use. Apply one drop per eye, then wait 1-2 minutes for maximal anesthesia. Blot excess to reduce systemic absorption. Monitor for corneal epithelial defects after use. |
| Patient Advice | Do not rub your eyes after the drops are applied, as the anesthetic may mask injury. · This medication is for use in a doctor's office only; do not take it home. · Temporary blurred vision and stinging may occur immediately after the drop. · Avoid driving or operating machinery until vision clears completely. · Inform your doctor if you have a history of corneal disease, glaucoma, or allergies to anesthetics. |